Skip to main content

Cancer Clinical Trials


Condition Description Investigator 

Contact Information 

Blood & Bone Marrow Transplant Clinical Trials

Blood & Bone Marrow Transplant

 NK Cells: Analysis of Natural Killer Cells in Hematopoietic Stem Cell Transplant Patients and Donors

Natural killer (NK) cells are a type of white blood cell that play an important role in fighting against viral infections. This study collects blood from the donor and the recipient of a hematopoietic stem cell transplant (HSCT) to look at the affect on NK Cells and the ability to fight against a range of viral infections. 
Williams, Stephanie
Laura Paulsen 

Blood & Bone Marrow Transplant

REACH1: A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease 

This study will help us better understand if taking ruxolitinib (the study drug) in combination with corticosteroids is safe and effective in people who have acute graft versus host disease (GVHD) a stem cell transplant.

For more information, click here.

Abidi, Muneer, H.
 
Laura Paulsen 
Blood & Bone Marrow Transplant
BMT Cord Blood Access Protocol: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) in Pediatric and Adult Patients with Hematologic Malignancies and other Indications

This is an access study in which umbilical cord blood used for bone marrow transplant is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study. 

For more information, click here.

Abdel-Mageed, Aly 
Laura Paulsen 
Blood & Bone Marrow Transplant
NYBB UCB: A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

Umbilical cord blood used for bone marrow transplant which is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study.
Abdel-Mageed, Aly 
Laura Paulsen 
Blood & Bone Marrow Transplant
Multiple Cord Blood: Allogeneic Stem Cell Transplantation Using Multiple Unrelated Donor Umbilical Cord Grafts

This research study will evaluate the ability of umbilical cord blood cells, which have been obtained from multiple unrelated donors, to serve as a source of stem cells for patients undergoing stem cell transplant. The use of a single unrelated umbilical cord blood unit is common for small pediatric patients requiring stem cell transplantation when a related or unrelated donor is not available. For larger patients, the use of more than one umbilical cord blood unit provides an adequate number of stem cells and increases the chances of successful engraftment and survival.
Abdel-Mageed, Aly 
 
Laura Paulsen 
Blood & Bone Marrow Transplant  A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies.

For more information, click here
CRCWM Physician Investigators CRCWM 
616.391.1230
www.crcwm.org 
Blood & Bone Marrow Transplant 
Brincidofovir: Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

This study is an access protocol to provide treatment of the investigational drug called brincidofovir (BCV) to treat the virus called adenovirus (AdV).

For more information, click here.

Duffner, Ulrich
Laura Paulsen
SHUB  The Spectrum Health Universal Biorepository provides a robust, diverse offering of high-quality research and potential diagnostic samples associated with relevant de-identified clinical data to investigators.  Cottingham, Sandra  Spectrum Health Biorepository
david.chesla@spectrumhealth.org
616.267.2629
S1415CD A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) 

For more information, click here.
CRCWM Physician Investigators CRCWM 
616.391.1230
www.crcwm.org
URCC 14040 YOCAS A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors  CRCWM Physician Investigators
CRCWM 
616.391.1230
www.crcwm.org

Brain Cancer Clinical Trials 

Alliance A071102 NEWLY DIAGNOSED GLIOBLASTOMA; MGMT Promoter Hypermethylation; Phase II/III; Veliparib/Placebo in Combination with Adjuvant Temozolomide

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
ACNS0332  COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptic Agent in Other Than Average Risk Medulloblastoma/PNET Patients.  Patients > 3 and <22 years at the time of diagnosis

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NCI 9671  Exceptional Responders Pilot study:  Molecular profiling of tumors from cancer patients who are Exceptional Responders

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
QOL Multisite EAQ-152  EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Adevanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - MATCH  MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131  Dasatinib in Patients with Tumors with DDR2 Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - A  Solid Tumors (Other than SC & NSCLC) or Lymphomas; Afatinib in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - B  Tumors with HER2 Activating Mutations; Treatment: Afatinib

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - C1  Crizotinib in Patients with Tumors with MET Amplification

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - C2  Crizotinib  in Patients with Tumors with MET Exon 14 Deletion

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - E  Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: AZD9291

For more information, click here.  
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - F  Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: Crizotinib

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - G  ROS1 Translocations (Other Than Patients with NSCLC); Treatment: Crizotinib

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - H  Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: Dabrafenib and Trametinib

For more information, click here
CRCWM Physician Investigators
 
CRCWM 
616.391.1230
www.crcwm.org 
 
EAY131 - J  Trametinib and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - L  Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - M  Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

For more information, click here.  
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - R  BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: Trametinib

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - S1  Trametinib in Patients with Tumors with NF1 Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - S2  Trametinib in Patients with Tumors with GNAQ or GNA 11 mutations

For more information, click here.
CRCWM Physician Investigators
CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - T  Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: GDC-0449 (vismodegib)

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - U  Tumors with NF2 Loss; Treatment: VS-6063 (defactinib) 

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EAY131 - W  Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - X  Dasatinib in Patients with Tumors with DDR2 Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - Y  AZD5363 in Patients with Tumors with AKT Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - Z1A  Binimetinibin Patients with Tumors (Other than Melanoma) with NRAS Mutations 

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - Z1B  MATCH Treatment Subprotocol Z1B:  Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC

For more information, click here
CRCWM Physician Investigators   CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - Z1D  Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - Z1E  Testing LOXO-101 as potentially targeted treatment in cancers with NTRK genetic changes

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - Z1I  Testing AZD1775 as a possible treatment in people who have cancer with BRCA mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
ASCO TAPUR  Targeted Agent and Profiling Utilization Registry Study. All drugs provided.

For more information, click here.  
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NCI PDM 9846  Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
SHUB  The Spectrum Health Universal Biorepository provides a robust, diverse offering of high-quality research and potential diagnostic samples associated with relevant de-identified clinical data to investigators.
Cottingham, Sandra Spectrum Health Biorepository
david.chesla@spectrumhealth.org
616.267.2629
URCC 13059
GAP-70 
Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
S1415CD  A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
URCC 04040 YOCAS  A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
Alliance A221101  HIGH GRADE GLIOMA/ Cancer Related Fatigue | Treatment: Armodafinil vs Placebo

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NRG CC003  Randomized Phase II/III Trial of Prophylactice Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer 

For more information, click here.
CRCWM Physician Investigators
CRCWM 
616.391.1230
www.crcwm.org 
NRG CC001  A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
A071401  Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

For more information, click here
CRCWM Physician Investigators   CRCWM 
616.391.1230
www.crcwm.org  
NCI 9671  Exceptional Responders Pilot study:  Molecular profiling of tumors from cancer patients who are Exceptional Responders

For more information, click here
CRCWM Physician Investigators   CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - MATCH  MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below

For more information, click here. 
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EAY131  Dasatinib in Patients with Tumors with DDR2 Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 

     
 Brain-CN (Neurology)  Brain-CN (Neurology) trials offered through Cancer Research Consortium of West Michigan.    

Breast Cancer Clinical Trials

Alliance A011104  Preoperative breast MRI on surgical outcomes, cost, and quality of life. Stage I-II; ER neg/PR neg & HER-2 neg breast OR ER neg/PR neg & HER-2 positive tumors 

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EA1141  Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NSABP B-51  Any ER/PR/HER2; NEOADJUVANT/ Staging: T1-3; Treatment: RT for patients who convert to path negative nodes after neoadjuvant Chemo and Surgery 

For more information, click here.
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
Breast
M12-914: A phase III randomized, placebo-controlled trial of carboplatin and paclitaxel +/- the PARP inhibitor, veliparib (ABT-888) in HER-2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer

The purpose of this study is to determine the effectiveness of veliparib in the treatment of locally advanced (spread to nearby tissue) or metastatic (spread to other parts of your body) HER 2-negative breast cancer and have been confirmed or highly suspected BRCA1 or BRCA2 mutation.  Secondarily, we will look at how the drug is absorbed, broken down and removed from your body; and look for biomarkers or early signs that the study drug is working. 

For more information, click here.

Melnik, Marianne 
Mollie Lockard
NRG BR003  TRIPLE NEGATIVE; Adjuvant;  HIGH RISK NODE(-)or NODE(+) / Invasive; A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NSABP B-55  TRIPLE NEGATIVE: BRCA+; Adjuvant; High Risk/ Treatment: Olaparib vs Placebo

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
A011502  A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer; the Aspirin for Breast Cancer Study (ABC Study)

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
AFT-05  PAFT-095 PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2 negative early breast cancer)

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
S1418  TRIPLE NEGATIVE: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Caqncer with >/=1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EA1131  TRIPLE NEGATIVE; Adjuvant; BASAL-LIKE  Breast Cancer; Phase III Post-Operative; Platinum Based Chemotherapy vs Observation in Patients with Residual following Neoadjuvant Chemotherapy

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
SWOG S1207  ER/PR(+) & HER2-;Adjuvant; Stage I-III; Oncotype Testing Required for Patients with <4 Positive Lymph Nodes.  Treatment: Endocrine Therapy + Everolimus/Placebo

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
CTSU E1Z11  BREAST - ER/PR+; Any HER2; Adjuvant / Stage I - III Adenocarcinoma | Treatment: Anastrozole. Only the Asian and Native Hawaiian/Pacific Islanders cohorts remain open to accrual

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
CTSU E2112  ER/PR+; Her2-; Stage IIIC or IV; Treatment: Endocrine Therapy plus Entinostat/Placebo

For more information, click here
CRCWM Physician Investigators   CRCWM 
616.391.1230
www.crcwm.org 
ACCRU RU011201I  Any ER/PR; HER2-; Stage IIIC or IV; not amenable to local therapy. Treatment: Eribulin vs Paclitaxel

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
S1416  Phase II Rancomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

For more information, click here
CRCWM Physician Investigators   CRCWM 
616.391.1230
www.crcwm.org 
RTOG 1119  Any ER/PR; Her2+; Metastatic; BRAIN METS. Treatment WBRT +/- Lapatinib

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
SCRI BRE 203  Any ER/PR/HER2; METASTATIC/  Stage IV Must be AR+ and fit into one of these: A. ER-/PR-/Her2-/AR+ with 1-3 previous treatment for metastatic disease. B. Postmenopausal ER+ and/or PR+/AR + refractory MCB with progression after 1-3 hormonal treatments. Treatment: Orteronel

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NRG CC003 Randomized Phase II/III Trial of Prophylactice Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
NRG CC001 A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
A071401 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
QOL Multisite EAQ-152  EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Adevanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling

For more information, click here.

CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EAY131 - MATCH  MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131  Dasatinib in Patients with Tumors with DDR2 Mutations

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EAY131 - A  Solid Tumors (Other than SC & NSCLC) or Lymphomas; Afatinib in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EAY131 - B  Tumors with HER2 Activating Mutations; Treatment: Afatinib 

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - C1  Crizotinib in Patients with Tumors with MET Amplification

For more information, click here
CRCWM Physician Investigators   CRCWM 
616.391.1230
www.crcwm.org  
EAY131 - C2  Crizotinib  in Patients with Tumors with MET Exon 14 Deletion

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - E  Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: AZD9291

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org  
EAY131 - F  Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: Crizotinib

For more information, click here
CRCWM Physician Investigators  CRCWM 
616.391.1230
www.crcwm.org 
EAY131 - G  ROS1 Translocations (Other Than Patients with NSCLC); Treatment: Crizotinib

For more information, click here
CRCWM Physician Investigators 
CRCWM 
616.391.1230
www.crcwm.org 
Breast 
PVB vs PNB: Paraverteberal Block Versus Pectoral Nerve Block for Analgesia Following Mastectomy

The purpose of this study is to compare two standard methods of pain control management used at Spectrum Health for patients undergoing breast surgery. 
Melnik, Marianne

Marianne Morissey 
cancer.research@spectrumhealth.org
616.486.8500

Breast
SOLAR 1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER 2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment 

The purpose for the study is to learn whether alpelisib, when added to a marketed standard treatment (fulvestrant), helps to reduce the growth of breast cancer cells in people with hormone receptor-positive, HER 2-negative advanced breast cancer.

For more information, click here.

Melnik, Marianne 
Mollie Lockard
Breast Breast cancer trials offered through Cancer Research Consortium of West Michigan.    
Colorectal  Colorectal trials offered through Cancer Research Consortium of West Michigan    
Genitourinary
CaPSURE: Cancer of the Prostate Strategic Urologic Research Endeavor Tissue Consent

This study is to determine the impact of prostate cancer on a patient’s well-being, study the use of tests and treatment in the care of prostate cancer, and help guide research towards better treatments. 
 Lane, Brian
Sue Engerman

Genitourinary 
ARAMIS: A multinational, randomized, double-blind, placebo-controlled, Phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer

This study is for men who have been on ADT for their recurrent prostate cancer and their PSA continues to rise without evidence of metastasis on imaging. The study drug  is an androgen deprivation therapy that deprives the cancer cells of testosterone needed for cancer growth.

For more information, click here.

Brede, Christopher 
Sue Engerman
Genitourinary
The Bladder Irrigation Comparison (BIC) Study: a Prospective, Open-Label Randomized Clinical Trial of a Single Bladder Instillationof Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately after Transurethral Resection of Bladder Tumor

This study is comparing three standard treatments post removal of a bladder tumor in surgery. Physicians are trying to learn which of these standard treatments provides the chance of preventing tumor recurrence with the least amount of side effects.

For more information, click here.

Humphrey, John
Sue Engerman
Genitourinary 
G Minor: Genomics in Michigan Impacting Observation or Radiation

The G-Minor study is for men who have had a radical prostatectomy with high risk factors on their pathology. We  are comparing two tests (the Capra-S Nomogram  and the  Decipher® Test)  to see how they affect the patient and physician's decisions regarding receiving additional treatment after surgery. The tests give a percent chance of the prostate cancer recurring or spreading in the future. 

For more information, click here.

Lane, Brian 
Sue Engerman
Genitourinary
INSTILADRIN: A Phase III, Open Label study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN/Syn3) Adminstered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer

This study if for patients who have high grade non-invasive bladder cancer T1, Ta or CIS and whose cancer has recurred despite receipt of BCG therapy. The study drug is an immunotherapy which helps the patients own body to fight the cancer cells. 

For more information, click here.

Lane, Brian
Sue Engerman
Genitourinary  Genitourinary (GU) trials offered through Cancer Research Consortium of West Michigan.      
Gynecologic  Gynecologic trials offered through Cancer Research Consortium of West Michigan.     
Head & Neck  Head & Neck trials offered through Cancer Research Consortium of West Michigan    
Leukemia  Leukemia trials offered through Cancer Research Consortium of West Michigan    
Lung  Lung trials offered through Cancer Research Consortium of West Michigan    
Lymphoma  Lymphoma trials offered through Cancer Research Consortium of West Michigan    
Melanoma  Melanoma trials offered through Cancer Research Consortium of West Michigan    
Mulitsite  Multisite trials offered through Cancer Research Consortium of West Michigan.
   
Myeloma  Myeloma trials offered through Cancer Research Consortium of West Michigan    
Sarcoma 
MSTA: Musculoskeletal Tumor Tissue Acquisition Protocol

This study will collect biospecimens and medical information for use in laboratory research to learn more about bone tumors and musculoskeletal diseases. Future research is focused on the prevention, diagnosis and treatment. 
Steensma, Matthew 
Heidi DeVries
Sarcoma
Genetic Outlier: The Identification of Novel Mutations in Outlier Patients

This study is to better understand more about germline mutations (hereditary mutations) in those that have unique circumstances surrounding their medical condition or the medical condition of a family member. Researchers are looking to develop a mechanism for discovery-level genetic research in individuals who have characteristics of a genetic disease or syndrome which cannot currently be linked to a known germline mutation.  Participation is by invitation only.
Steensma, Matthew 
Heidi DeVries
Sarcoma
Femoral Met Repair: A prospective, randomized surgical trial comparing postoperative functional outcomes among cancer patients treated with long-stem cemented hemiarthroplasty (LSCH) verses intramedullary nail (IMN) for pathologic subtrochanteric femur fractures

This study is being done to look at two different types of surgeries routinely used for treating metastases, the spread of cancer in the upper portion of the femur.
Steensma, Matthew  
Heidi DeVries
Sarcoma  Sarcoma trials offered through Cancer Research Consortium of West Michigan    
Unknown Primary  Unknown Primary trials offered through Cancer Research Consortium of West Michigan    
Upper Gastrointestinal  TXA: Evaluating the effect of Tranexamic Acid on blood lost and transfusion rates in major oncologic surgeries

This study looks at the use of tranexamic acid in hopes that it will decrease bleeding related to major surgery, resulting in reduced blood loss, lower blood transfusion rates, and possibly decreased hospital costs related to your surgical hospital stay. 
Chung, Mathew 
Eric Laney 
Upper Gastrointestinal  Upper Gastrointestinal (UGI) trials offered by Cancer Research Consortium of West Michigan    

For other clinical trials available for cancer health, visit Cancer Consortium of West Michigan at: www.crcwm.org. You can also visit clinicaltrials.gov for opportunities internationally.